Treatment of Hemophilia with Glycine-Precipitated Factor VIII

Abstract

EFFECTIVE hemostasis can be achieved in most simple bleeding episodes of classic hemophilia by the use of fresh, fresh-frozen or lyophilized plasma as the source of antihemophilic factor (AHF, factor VIII). In the event of major trauma or surgical procedures sustained levels of 20 to 30 per cent of factor VIII are necessary to provide hemostasis. Such levels are often impossible to achieve with the use of plasma, and attempts to maintain hemostasis with repeated infusions may lead to congestive heart failure owing to the resulting overexpansion of total plasma volume. Recently, concentrated forms of factor VIII that provide safer . . .